Abstract
Patients suffering from dental infections and concurrently using immunosuppressive medication are at increased risk of developing systemic streptococcal infections. Tocilizumab is a novel therapeutic agent targeting interleukin-6. We describe a case of streptococcal lung abscesses from a dental focus after use of tocilizumab for treatment of Takayasu arteritis.
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 951-953 |
| Number of pages | 3 |
| Journal | Clinical & Experimental Rheumatology |
| Volume | 30 |
| Issue number | 6 |
| Publication status | Published - 2012 |